1. Home
  2. MMI vs SPRY Comparison

MMI vs SPRY Comparison

Compare MMI & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMI

Marcus & Millichap Inc.

HOLD

Current Price

$29.15

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$9.60

Market Cap

969.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMI
SPRY
Founded
1971
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
969.2M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
MMI
SPRY
Price
$29.15
$9.60
Analyst Decision
Sell
Strong Buy
Analyst Count
2
1
Target Price
$28.00
$40.00
AVG Volume (30 Days)
211.4K
1.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
1.78%
N/A
EPS Growth
84.38
N/A
EPS
N/A
N/A
Revenue
$719,700,000.00
$84,278,000.00
Revenue This Year
$14.04
$87.40
Revenue Next Year
$11.35
$81.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.43
$6.66
52 Week High
$33.62
$18.63

Technical Indicators

Market Signals
Indicator
MMI
SPRY
Relative Strength Index (RSI) 49.23 56.70
Support Level $27.47 $9.50
Resistance Level $31.03 $9.63
Average True Range (ATR) 0.92 0.57
MACD -0.12 0.06
Stochastic Oscillator 41.07 60.54

Price Performance

Historical Comparison
MMI
SPRY

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: